The program includes contraceptive pills, condoms, the government-provided 'Nirodh' brand, intra-uterine contraceptive devices, female and male sterilization
An innovative contraceptive named 'Levormeloxifene' (1✔ ✔Trusted Source
Levormeloxifene
Go to source), an enhanced 90's contraceptive 'Saheli' with minimal chemicals has been unveiled by the CSIR-Central Drug Research Institute (CDRI) in Lucknow. The breakthrough contraceptive is notably more effective to the human body with its reduced dose and chemical burden compared to existing market options. Once a staple during the 1990s, Saheli, also known as 'Chaya' under the National Family Planning programme, has now evolved into Levormeloxifene.
Development of Levormeloxifene as a Targeted Contraceptive
Radha Rangarajan, Director of CSIR-CDRI, explained, "The core objective behind this contraceptive's development was to minimize the chemical content, particularly crucial for women in their reproductive phase who predominantly consume such tablets." Rangarajan elaborated, "The compound ormeloxifene within Saheli comprises two enantiomers, dextro-ormeloxifene, and levo-ormeloxifene (levormeloxifene). Extensive preclinical studies have indicated higher efficacy of the levo counterpart, levormeloxifene. This research solely focuses on testing the levo model as a contraceptive, thereby reducing the unnecessary use of dextro-ormeloxifene and alleviating women from undue chemical exposure."‘Levormeloxifene, developed by CDRI, is an updated iteration of the 1990s 'Saheli' contraceptive pill. #BirthControlPills #Contraceptives’
The development of this groundbreaking contraceptive is the culmination of a decade-long intensive research effort led by a team of scientists, including Wahajul Haq, Vivek Bhosle, Arun Trivedi, Rajesh Jha, Rabi Bhatta, Sharad Sharma, SK Rath and others. Upon successful clinical trials, this contraceptive will bolster family planning initiatives, adding to the existing range of contraceptive services within the programme. Notably, Cipla has received approval from the Drugs Controller General of India to conduct Phase-I clinical trials for Levormeoxifene. (2✔ ✔Trusted Source
Recommendations of the SEC meeting to examine IND proposals
Go to source) This investigational drug is a collaborative effort between Cipla and CSIR-CDRI, Lucknow, aimed at developing an oral, non-hormonal contraceptive solution.
References:
- Levormeloxifene - (https://pubchem.ncbi.nlm.nih.gov/compound/35805)
- Recommendations of the SEC meeting to examine IND proposals - (https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Minutes%20of%20IND%20Committee%20meeting%20held%20on%2005.06.2023.pdf)